Lucence

Lucence Diagnostics is a genomic medicine company focused on personalising cancer care. It has developed a full spectrum of cancer diagnostics covering early-stage screening to late-stage treatment selection with a special focus on common cancers in Asia.

Lucence's proprietary product is LiquidHALLMARK, a 'clinical sequencing blood test that detects cancel-related genetic mutations and cancer-causing viruses with a single assay', and can spot fourteen different types of cancer.

Lucence's tests are primarily used in SE Asia, however it is planning to expand further into North America and East Asia in 2020. It is also in the process of building a new lab in California.

In November 2019, Lucence raised a $20m Series A round led by private healthcare group IHH Healthcare. The company plans to use the funding to scale Lucence's labs, expanding its team, and to improve its commercial presence in Asia and North America. The funding will also be put towards two new clinical trials. 

Its headquarters is in Singapore and the company has offices in San Francisco and Hong Kong.